Anderson Raymond reported option exercise involving 1,740 derivative units of Monopar Therapeutics at $0.00 for $0 on Nov 2, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 4, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
1,740Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
1,740Direct
Trade date
Nov 2, 2026Option exercise
Filed
Nov 4, 2026, 8:15 PM ET3-day reporting delay
Accession
0001437749-26-035040Code M · Transaction 393036
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 2, 2026Option exercise1,402$0.00$0Trade 393035
Nov 2, 2026Sell840$66.16−$55,574.40Trade 393031
Nov 2, 2026Sell600$67.06−$40,236Trade 393032
Nov 2, 2026Sell200$68.68−$13,736Trade 393033
Nov 2, 2026Sell1,502$70.04−$105,200.08Trade 393034
Nov 2, 2026Option exercise1,402$30.00$42,058.04Trade 393029
Nov 2, 2026Option exercise1,740$30.00$52,200Trade 393030
8 transaction rows in this filing. Joint filers share the same rows.

MNPR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MNPR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +16%1w ago +4.9%1d ago +4.6%
Returns since7d +6.7%30d90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-26-2026. F2: On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter. F3: On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.56 to $66.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.88 to $67.57, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.59 to $68.77, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.02 to $70.32, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (7) to this Form 4.